0.0564
-0.0049 (-7.99%)
-0.0049 (-7.99%)
Upgrade to Real-Time
Market Closed
| Volume | 283,369 |
|
|||||
| News | - | ||||||
| Day High | 0.0615 | Low High |
|||||
| Day Low | 0.0562 | ||||||
Best deals to access real time data! |
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Provectus Biopharmaceuticals Inc (QB) | PVCT | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| -0.0049 | -7.99% | 0.0564 | 15:15:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.0615 | 0.0562 | 0.0615 | 0.0564 | 0.0613 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 20 | 283,369 | $ 0.060344 | $ 17,100 | - | 0.0421 - 0.0779 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:15:03 | 750 | $ 0.0564 | USD |
Period:
Draw Mode:
Provectus Biopharmaceuticals Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 23.66M | 419.45M | 381.51M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 212.00 | $ - | - | - | - |
Provectus Biopharmaceuti... (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PVCT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0537 | 0.062 | 0.0512 | 0.0560076 | 85,508 | 0.0027 | 5.03% |
| 1 Month | 0.062 | 0.0686 | 0.045 | 0.057744 | 215,958 | -0.0056 | -9.03% |
| 3 Months | 0.0689 | 0.0725 | 0.045 | 0.0608749 | 221,442 | -0.0125 | -18.14% |
| 6 Months | 0.0515 | 0.0734 | 0.0421 | 0.0590348 | 238,393 | 0.0049 | 9.51% |
| 1 Year | 0.0675 | 0.0779 | 0.0421 | 0.0611618 | 266,072 | -0.0111 | -16.44% |
| 3 Years | 0.052 | 0.13 | 0.0005 | 0.0638334 | 299,431 | 0.0044 | 8.46% |
| 5 Years | 0.04745 | 0.13 | 0.0005 | 0.0596457 | 365,246 | 0.00895 | 18.86% |
Provectus Biopharmaceuti... (QB) Description
| Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing a new class of drugs for oncology, hematology, and dermatology based on an entire, wholly-owned, family of chemical small molecules called halogenated xanthenes. Intratumoral (aka intralesional) PV-10, the first small molecule autolytic immunotherapy, which can induce immunogenic cell death, is undergoing clinical study for adult solid tumor cancers, such as melanoma and GI tumors (e.g., hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic uveal melanoma), and preclinical study for pediatric solid tumor cancers (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma) and blood cancers (e.g., acute myeloid leukemia). Topical PH-10 is undergoing clinical study for inflammatory dermatoses (e.g., psoriasis, atopic dermatitis). Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com. |